This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human B7-1 / CD80 Protein, His Tag (MALS verified)
catalog :
B71-H5228
quantity :
100 ug, 1 mg
price :
280 USD, 1700 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
B71-H5228
product name :
Human B7-1 / CD80 Protein, His Tag (MALS verified)
quantity :
100 ug, 1 mg
price :
280 USD, 1700 USD
quantity & price :
$280/100ug,$1700/1mg
target :
B7-1
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human B7-1, His Tag (B71-H5228) is expressed from human 293 cells (HEK293). It contains AA Val 35 - Asn 242 (Accession # P33681-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human B7-1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
B7-1 and B7-2, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T and Bcell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B71 and B72 with a 20 100 fold higher affinity than CD28 and is involved in the downregulation of the immune response.
B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.
References :
(1) Peach RJ., et al., 1995, J. Biol. Chem. (UNITED STATES) 270 (36): 21181–7.
(2) Stamper CC., et al., 2001, Nature (England) 410 (6828): 608–11.
(3) Bhatia S., et al., 2005, Proc. Natl. Acad. Sci. 102: 15569-15574.
(4) Khan N., et al., 2007, Int. Immunol. 19:477-486.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments